RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.

Rapid Therapeutic Science Laboratories, Inc.

RTSL

US7534312043

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 12:34:46 2024-05-03 EDT			5-day change	1st Jan Change
0.005 ^USD	0.00%		0.00%	+21.95%

2023	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
2023	Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

November 10, 2021 at 09:56 am

Rapid Therapeutic Science Laboratories, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was USD 0.00005 million compared to USD 0.001629 million a year ago. Net loss was USD 0.583442 million compared to USD 0.640536 million a year ago.
For the nine months, sales was USD 0.000474 million compared to USD 0.140055 million a year ago. Net loss was USD 1.65 million compared to USD 1.52 million a year ago. Basic loss per share from continuing operations was USD 0.25 compared to USD 0.25 a year ago.

Latest news about Rapid Therapeutic Science Laboratories, Inc.

Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt	23-03-29	CI
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.35 million in funding	22-05-30	CI
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-11	CI
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-16	CI
Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt	22-03-15	CI
Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.4 million in funding	22-01-27	CI
Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.15375 million in funding from Sixth Street Lending, LLC	22-01-17	CI
Rapid Therapeutics Science Laboratories Announces Launch of its New Facility Located in Addison, Tex	21-11-11	CI
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-10	CI
Rapid Therapeutic Science Laboratories Appoints Justin Suggs to Its Board of Directors	21-11-02	CI
Rapid Therapeutic Science Laboratories, Inc. Appoints Henry A. Punzi, as A Member of the Board of Directors	21-08-25	CI
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-11	CI
Rapid Therapeutic Science Laboratories, Inc. Appoints J. Scott Suggs as Member of the Board of Directors and as Chairperson (And Sole Member) of the Company's Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee	21-08-05	CI
Rapid Therapeutic Science Laboratories, Inc. announced that it has received $1.65 million in funding from Armistice Capital LLC	21-08-03	CI
Rapid Therapeutic Science Laboratories, Inc. announced that it expects to receive $1.65 million in funding from Armistice Capital LLC	21-07-31	CI
Rapid Therapeutic Finalizes Lab Work on Pharmaceutical Formulas	21-06-10	CI
Rapid Therapeutic Prepares to File Investigational New Drug Application for its CBD Metered Dose Inhaler with FDA	21-06-02	CI
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-14	CI
Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Nine Months Ended December 31, 2020	21-03-16	CI
Empower : Holley to Go Public in Merger With Bank-Check Company Empower	21-03-12	MT

Chart Rapid Therapeutic Science Laboratories, Inc.

Duration

Period

Chart Rapid Therapeutic Science Laboratories, Inc.

More charts

Company Profile

Rapid Therapeutic Science Laboratories, Inc. is a biopharmaceutical company. The Company is focused on developing potential commercial opportunities which involve the rapid application of therapeutics using inhaler technology. The Company has developed a method of formulating and manufacturing pressurized metered dose inhalers (pMDI) that contain and properly aerosolize proprietary formula of one or more patent pending pharmaceutical-grade cannabinoid compounds. It has developed and is continuing to develop a series of complementary products in addition to its inhaler. It is also focusing on manufacturing its own branded MDI under the nhaler brand name.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Alternative Medicine

	1st Jan change	Capi.
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.	+21.95%	94.93K
DONG-E-E-JIAO CO.,LTD.	+45.15%	6.38B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-14.00%	4.59B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+9.54%	3.39B
TASLY PHARMACEUTICAL GROUP CO., LTD	-8.99%	3.2B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+50.03%	2B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-6.97%	1.7B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-0.31%	1.65B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+50.00%	1.55B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-10.61%	1.58B

Alternative Medicine